Petrelintide ↗ cut body weight by as much as 9.2 percent in people who have both obesity and type 2 diabetes, and almost no one dropped out because of nausea or vomiting. Zealand Pharma reported the topline numbers ↗ on October 7 from ZUPREME-2, a 28-week Phase 2 trial, and the tolerability figure is the one worth staring at.
Petrelintide is an amylin analog. Amylin is a hormone the pancreas releases alongside insulin, and it tells the brain the body has eaten enough. The drug copies that signal with a once-weekly injection, which puts it in a different class from the GLP-1 ↗ shots most people have heard of, like Wegovy and Zepbound. The entire commercial case for amylin drugs rests on one claim: they curb appetite with less of the stomach upset that makes people quit GLP-1 therapy. ZUPREME-2 is the first test of that claim in a diabetes population, which is a harder setting than obesity alone.
The trial randomized 220 US adults who were overweight or obese and had type 2 diabetes, starting at an average body mass index of 36.3 and an average HbA1c of 8.0 percent. HbA1c is the standard three-month blood-sugar average, and 8.0 sits above the 7 percent most doctors aim for. Across three dose groups, average weight fell between 7.4 and 9.2 percent, against 2.0 percent on placebo, measured on an estimate that assumes everyone stayed on treatment. Blood sugar moved too: HbA1c dropped by as much as 0.65 percentage points on petrelintide while it rose 0.23 points on placebo.
Then the dropout number. Only 1.9 percent of people on petrelintide stopped because of gastrointestinal side effects, against 1.7 percent on placebo. In plain terms, quitting for nausea was no more common on the drug than on a dummy injection. That is the figure the amylin thesis lives or dies on, and in a diabetes cohort it held.
Weight loss of 9.2 percent is not a headline number next to tirzepatide, where diabetes trials have cleared 12 to 15 percent. Semaglutide ↗ and the dual incretin drugs lose more weight. But they also carry double-digit nausea and vomiting rates, and in type 2 diabetes, where patients are often older and taking several other medicines, tolerability is not a footnote. A drug that delivers most of the weight effect with placebo-level dropouts is a real position in the market, not a consolation prize.
The caveats are the usual topline caveats. These are company-reported numbers, not a peer-reviewed paper, and Zealand says full results will come at a scientific meeting. The 9.2 percent is the top dose; the low end of the range is 7.4. Twenty-eight weeks is short, and in earlier amylin trials the weight curve had not clearly flattened by that point, so the Phase 3 program that Zealand and partner Roche began in September will run longer and larger.
ZUPREME-2 is the diabetes companion to ZUPREME-1 ↗, the obesity-only trial that read out in June with a similar tolerability story. Petrelintide targets the calcitonin receptor ↗, the same receptor the amylin half of CagriSema ↗ hits. The read-through for the amylin field is narrow but clear. The tolerability advantage that reopened the amylin case this spring survived contact with a diabetes population. Whether it survives contact with Phase 3 is the next question.